




PHARMACEUTICAL 2019

Rezolute Inc.
Rank 360 of 363





PHARMACEUTICAL 2019

Rezolute Inc.
Rank 360 of 363

The relative strengths and weaknesses of Rezolute Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rezolute Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 162% points. The greatest weakness of Rezolute Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 621% points.

The company's Economic Capital Ratio, given in the ranking table, is -818%, being 855% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	2,008
Cost of Goods Sold	0
Intangible Assets	37
Liabilities, Current	6,248
Liabilities, Non-Current	216
Other Assets	90
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,128
Other Revenues	0
Property and Equipment	368
Research and Development	17,280
Selling, General and Administrative Expense	11,455

Output Variable	Value in 1000 USD
Assets	2,503
Liabilities	6,464
Expenses	28,734
Revenues	0
Stockholders Equity	-3,961
Net Income	-29,862
Comprehensive Net Income	-29,862
Economic Capital Ratio	-818%